And so has the interest in this company, at least in the short-term.
We need the peer-review completed and the hTERT trial started before this thing will move upwards.
Until then, we trade between 10.50 and 11.50.
You'll see the "fear" at the open and during early morning, then buying later in the afternoon at deflated prices. Possible good entry point, but now not de-risked as much as before.
Not a chance, with the PR that came out this morning.
Maybe later, at some other time. But not anytime soon.
To use Kim's now infamous sport analogies.
But it's still only the first quarter. Plenty of time left to get into the end zone.
Nice try and guess, D.
Better subtract a zero from your estimate in the short-term and add a few years to your target in the long-term.
But it's early in the 1st quarter, so nothing to fear, right?
I think it will be off closer to $1 off than the "pennies" that you cite in your post.
You're deluded to the point of resorting to ad hominem attacks. My portfolio is likely much larger than yours, even with the small loss I'm taking in INO (on paper) this morning.
You're deluded to the point that you probably think it will actually turn green, today, I'm sure...
ALL pre-clinical development-stage biotech companies "live" for partnerships, or they MUST dilute or die.
No matter how one spins the news this morning, it's not positive for cancer patients or shareholders in the short-term.
This is not a one day loss, this is a STRATEGIC loss. Don't you get it?
In addition to diluting for VGX-3100 they will now also have to likely dilute for the prostate studies. Unless they find a different partner, which will be much more difficult now that this agreement has been terminated.
I haven't sold a single share, but I am VERY concerned by what just happened.
About the only thing we'll see in 2015 is dilution to fund VGX-3100 and also now the prostate studies will need internal funding...
ONCS is clearly the better investment in the short-term. (And maybe even in the long-term.)
They have 5-6 catalysts lined up BEFORE EOY and a new partnership may be one of them. The PPS will be $1+ by EOY or within 3 months. 100% return in 3 months will be much better than INO in 3 months.
In the short-term ONCS has clearly more upside and ROI potential than does INO. Especially with the news that came out this morning.
ONCS will meet ALL of their remaining milestones for 2014 within the next 6 weeks. There will be positive PR every single week through the end of the year. We may very well see 100%+ gains from here through EOY.
I'm still invested in INO (for longer-term), but ONCS is where the real action is at the next 6 weeks.
You are correct. I am a moron in your mind. But you're just one.
Thousands think I'm not.
And yes, we're all legends in our own mind.